Critical reviews in oncology/hematologyJan 4, 2026

Long Noncoding RNAs as Key Controllers of Cell Recycling in Cancer Linked to Drug Resistance and Treatment Response

Longevity & Aging Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 5, 2026

Abstract

Long noncoding RNAs (lncRNAs) are vital regulators of autophagy, a process that can both support cancer progression and enhance therapeutic resistance.

LncRNAs may regulate autophagy through mechanisms such as acting as competing endogenous RNAs or interacting directly with key autophagy proteins.
They can modulate important signaling pathways, including PI3K/AKT/mTOR and Wnt/β-catenin, influencing tumor cell behavior.
Autophagy's effects are context-dependent; lncRNA-driven autophagy may either promote drug resistance and tumor progression or exert tumor-suppressive effects.
Targeting the relationship between lncRNAs and autophagy could help overcome chemoresistance or enhance the effectiveness of cancer therapies.
Recent advancements in RNA-based treatments and small-molecule autophagy modulators may lead to new options for cancer treatment.

Simplified

Long noncoding RNAs (lncRNAs) have emerged as pivotal regulators of autophagy, a fundamental cellular process that maintains homeostasis under stress but also contributes to cancer progression and therapeutic resistance. Recent studies reveal that lncRNAs orchestrate autophagy through diverse mechanisms, including acting as competing endogenous RNAs (ceRNAs), directly interacting with core autophagy machinery such as Beclin1 and ATG proteins, or modulating key signaling pathways like PI3K/AKT/mTOR, Wnt/β-catenin, and HIF-1α. By fine-tuning autophagic activity, lncRNAs shape tumor cell survival, proliferation, and response to chemotherapy, targeted therapy, and radiotherapy. Importantly, the impact of autophagy is highly context-dependent: in some settings, lncRNA-driven autophagy promotes drug resistance and tumor progression, whereas in others, autophagy induction exerts tumor-suppressive effects. Targeting the lncRNA-autophagy axis therefore offers dual opportunities: inhibiting pro-autophagic lncRNAs to overcome chemoresistance, or restoring anti-autophagic lncRNAs to sensitize tumors to treatment. Advances in RNA-based therapeutics and delivery platforms, coupled with small-molecule autophagy modulators and immunotherapy, provide new avenues for translational applications. In this review, we summarize current knowledge of lncRNA-mediated autophagy in cancer, highlight its role in therapeutic resistance and sensitization, and discuss challenges and opportunities for clinical translation.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declaration of Competing Interest The authors declare that there are no conflicts of interest regarding the publication of this paper.

PubMed

Long Noncoding RNAs as Key Controllers of Cell Recycling in Cancer Linked to Drug Resistance and Treatment Response

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the longevity & aging brief